	US 11,744,851 B2
	Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
Shannon E. Boye, Gainesville, FL (US); and Sanford L. Boye, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Sep. 7, 2021, as Appl. No. 17/467,555.
Application 17/467,555 is a continuation of application No. 16/914,230, filed on Jun. 26, 2020, granted, now 11,141,425.
Claims priority of provisional application 62/867,596, filed on Jun. 27, 2019.
Prior Publication US 2022/0062325 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/728 (2006.01); A61K 9/00 (2006.01); A61P 17/00 (2006.01); C07K 16/28 (2006.01); A61K 35/761 (2015.01); A61K 9/51 (2006.01); A61K 39/00 (2006.01)

CPC A61K 31/728 (2013.01) [A61K 9/0019 (2013.01); A61K 9/5184 (2013.01); A61K 35/761 (2013.01); A61P 17/00 (2018.01); C07K 16/2875 (2013.01); A61K 2039/5258 (2013.01); A61K 2800/91 (2013.01)]

18 Claims

1. A composition comprising a rAAV particle comprising: (a) a capsid admixed with hyaluronic acid and (b) a polynucleotide encoding a therapeutic agent, wherein the hyaluronic acid has an average molecular weight of 4 kDa to 5,000 kDa, wherein the therapeutic agent (a) preserves one or more photoreceptor cells, one or more retinal ganglion cells, one or more retinal bipolar cells, or one or more retinal pigment epithelial (RPE) cells; (b) restores one or more rod-and/or cone-mediated functions; (c) restores visual behavior in one or both eyes; or (d) any combination thereof.